Review: Evidence for CGRP Migraine Drugs in Children Rests on One Randomized Trial and a Handful of Real-World Studies
A narrative review published October 14, 2026 in Current Pain and Headache Reports found that the evidence for CGRP-targeting migraine treatments in people under 18 consists of one randomized controlled trial, of fremanezumab (Ajovy) in children aged 6 to 17 with episodic migraine, which showed benefit, plus several small real-world studies. CGRP drugs have been used in adults since 2018, and the authors said trials of other CGRP-targeting drugs in children are still pending.